← Leaderboards
Tony Wyss-Coray
J. David Gladstone Institutes
$32,197,912
Attributed
$37,252,297
Total exposure
26
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,966,122 · 22
VA$0 · 5
By mechanism
R01$15,957,718 · 9
RF1$9,558,789 · 3
U01$7,315,052 · 2
DP1$3,653,500 · 1
P30$1,936,343 · 2
T32$1,424,028 · 1
Top collaborators
- Luis De Lecea7 shared
- Thomas A Rando5 shared
- Aaron D. Gitler4 shared
- Jian Luo1 shared
- Vyjeyanthi S Periyakoil1 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposCellsBrainS DiseaseAgingLeadNerve DegenerationPlasmaBaseAffectNeurodegenerative DisordersNeuronsMolecularDementiaTissuesProteinsImpaired CognitionPathway InteractionsMediatingIn VivoCognitive FunctionParabiosisAge RelatedInflammation
Grant awards (99)
Molecular signature of parabiosis$462,757
R01 · FY2025 · AG · contact PI
Molecular signature of parabiosis$472,200
R01 · FY2024 · AG · contact PI
Biomarker Core$368,403
P30 · FY2024 · AG · contact PI
Stanford Training Program in Aging Research$103,408
T32 · FY2024 · AG · contact PI
Stanford Training Program in Aging Research$483,724
T32 · FY2023 · AG · contact PI
Molecular signature of parabiosis$472,200
R01 · FY2023 · AG · contact PI
Biomarker Core$344,748
P30 · FY2023 · AG · contact PI
2023 Biology of Aging Gordon Research Conference and Gordon Research Seminar$49,940
R13 · FY2023 · AG · contact PI
Molecular signature of parabiosis$472,756
R01 · FY2022 · AG · contact PI
Biomarker Core$400,564
P30 · FY2022 · AG · contact PI
Stanford Training Program in Aging Research$388,312
T32 · FY2022 · AG · contact PI
Biomarker Core$477,880
P30 · FY2021 · AG · contact PI
Molecular signature of parabiosis$472,922
R01 · FY2021 · AG · contact PI
Stanford Training Program in Aging Research$448,584
T32 · FY2021 · AG · contact PI
Biomarker Core$344,748
P30 · FY2020 · AG · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2020 · VA · contact PI
Microglial dysfunction in brain aging and Alzheimer's disease$0
I01 · FY2020 · VA · contact PI
Microglial lipid droplets in Alzheimer's disease$3,681,800
RF1 · FY2019 · AG · contact PI
Targeting CD22 to Restore Brain Homeostasis in Alzheimer's Disease$2,458,073
RF1 · FY2019 · AG · contact PI
A Bioorthogonal Approach to Study Mammalian Aging$785,000
DP1 · FY2019 · AG · contact PI
Targeting CD22 to Restore Brain Homeostasis in Alzheimer's Disease$439,951
RF1 · FY2019 · AG · contact PI
BLR&D Research Career Scientist Award Application$0
IK6 · FY2019 · VA · contact PI
Microglial dysfunction in brain aging and Alzheimer's disease$0
I01 · FY2019 · VA · contact PI
Targeting Cerebrovascular TGF Signaling in Alzheimer's Disease$2,978,965
RF1 · FY2018 · AG
A Bioorthogonal Approach to Study Mammalian Aging$785,000
DP1 · FY2018 · AG · contact PI
Optogenetic interrogation of sleep circuits during aging$470,978
R01 · FY2018 · AG
A Bioorthogonal Approach to Study Mammalian Aging$322,535
DP1 · FY2018 · AG · contact PI
Core D: Neuropathology Core$183,210
P50 · FY2018 · AG · contact PI
Aging and Inflammation in Mild Traumatic Brain Injury$0
I01 · FY2018 · VA · contact PI
A New Muscle-Brain Axis Underlying the Cognitive Benefits of Physical Activity$693,713
R01 · FY2017 · AG · contact PI
A Bioorthogonal Approach to Study Mammalian Aging$371,965
DP1 · FY2017 · AG · contact PI
Optogenetic interrogation of sleep circuits during aging$353,071
R01 · FY2017 · AG
Circulatory Rejuvenating Factors for the Brain$289,050
R01 · FY2017 · AG · contact PI
Core D: Neuropathology Core$183,736
P50 · FY2017 · AG · contact PI
Optogenetic interrogation of sleep circuits during aging$163,041
R01 · FY2017 · AG
Optogenetic interrogation of sleep circuits during aging$92,631
R01 · FY2017 · AG
Aging and Inflammation in Mild Traumatic Brain Injury$0
I01 · FY2017 · VA · contact PI
Aging and Inflammation in Mild Traumatic Brain Injury$0
I01 · FY2017 · VA · contact PI
A Bioorthogonal Approach to Study Mammalian Aging$694,500
DP1 · FY2016 · AG · contact PI
A New Muscle-Brain Axis Underlying the Cognitive Benefits of Physical Activity$693,713
R01 · FY2016 · AG · contact PI
Optogenetic interrogation of sleep circuits during aging$352,856
R01 · FY2016 · AG
Circulatory Rejuvenating Factors for the Brain$289,050
R01 · FY2016 · AG · contact PI
ShEEP Request for Confocal Microscope$0
IS1 · FY2016 · VA · contact PI
A Bioorthogonal Approach to Study Mammalian Aging$694,500
DP1 · FY2015 · AG · contact PI
A New Muscle-Brain Axis Underlying the Cognitive Benefits of Physical Activity$672,901
R01 · FY2015 · AG · contact PI
Optogenetic interrogation of sleep circuits during aging$342,069
R01 · FY2015 · AG
Circulatory Rejuvenating Factors for the Brain$280,378
R01 · FY2015 · AG · contact PI
Core D: Neuropathology Core$165,771
P50 · FY2015 · AG · contact PI
Beclin Deficiency and Microglial Impairment in Alzheimer's Disease$0
I01 · FY2015 · VA · contact PI
Aging and Inflammation in Mild Traumatic Brain Injury$0
I01 · FY2015 · VA · contact PI
A New Muscle-Brain Axis Underlying the Cognitive Benefits of Physical Activity$693,713
R01 · FY2014 · AG · contact PI
Optogenetic interrogation of sleep circuits during aging$367,575
R01 · FY2014 · AG
Circulatory Rejuvenating Factors for the Brain$289,050
R01 · FY2014 · AG · contact PI
Beclin Deficiency and Microglial Impairment in Alzheimer's Disease$0
I01 · FY2014 · VA · contact PI
Aging and Inflammation in Mild Traumatic Brain Injury$0
I01 · FY2014 · VA · contact PI
Development of an Agonist of the TGF-beta Signaling Pthway to Treat Alzheimer's$1,067,411
U01 · FY2013 · NS · contact PI
Development of an Agonist of the TGF-beta Signaling Pathway to Treat Alzheimer's$1,040,009
U01 · FY2013 · NS · contact PI
A New Muscle-Brain Axis Underlying the Cognitive Benefits of Physical Activity$775,047
R01 · FY2013 · AG · contact PI
Circulatory Rejuvenating Factors for the Brain$289,050
R01 · FY2013 · AG · contact PI
Beclin 1 Neurodegeneration and Alzheimer's Disease$237,586
R01 · FY2013 · AG · contact PI
Development of an Agonist of the TGF-beta Signaling Pathway to Treat Alzheimer's$140,000
U01 · FY2013 · NS · contact PI
Beclin Deficiency and Microglial Impairment in Alzheimer's Disease$0
I01 · FY2013 · VA · contact PI
Development of an Agonist of the TGF-beta Signaling Pathway to Treat Alzheimer's$861,758
U01 · FY2012 · NS · contact PI
Development of an Agonist of the TGF-beta Signaling Pthway to Treat Alzheimer's$861,758
U01 · FY2012 · NS · contact PI
Beclin 1 Neurodegeneration and Alzheimer's Disease$251,413
R01 · FY2012 · AG · contact PI
Beclin Deficiency and Microglial Impairment in Alzheimer's Disease$0
I01 · FY2012 · VA · contact PI
Development of an Agonist of the TGF-beta Signaling Pathway to Treat Alzheimer's$519,203
U01 · FY2011 · NS · contact PI
Development of an Agonist of the TGF-beta Signaling Pthway to Treat Alzheimer's$519,203
U01 · FY2011 · NS · contact PI
Beclin 1 Neurodegeneration and Alzheimer's Disease$251,413
R01 · FY2011 · AG · contact PI
Development of an Agonist of the TGF-beta Signaling Pathway to Treat Alzheimer's$626,492
U01 · FY2010 · NS · contact PI
Development of an Agonist of the TGF-beta Signaling Pthway to Treat Alzheimer's$626,492
U01 · FY2010 · NS · contact PI
TGFbeta signaling in neurodegeneration and Alzhimer's$270,372
R01 · FY2010 · AG · contact PI
Beclin 1 Neurodegeneration and Alzheimer's Disease$261,562
R01 · FY2010 · AG · contact PI
TGFbeta Signaling in Neurodegeneration and Alzheimer's$273,104
R01 · FY2009 · AG · contact PI
Beclin 1 Neurodegeneration and Alzheimer's Disease$264,204
R01 · FY2009 · AG · contact PI
Development of an Agonist of the TGF-beta Signaling Pthway to Treat Alzheimer's$526,363
U01 · FY2008 · NS · contact PI
Development of an Agonist of the TGF-beta Signaling Pathway to Treat Alzheimer's$526,363
U01 · FY2008 · NS · contact PI
TGFbeta Signaling in Neurodegeneration and Alzheimer's$273,104
R01 · FY2008 · AG · contact PI
TGFbeta Signaling in Neurodegeneration and Alzheimer's$254,790
R01 · FY2007 · AG · contact PI
Drug Agonists of TGFbeta Signaling to Treat Alzheimer's$128,948
R21 · FY2007 · AG · contact PI
Controlled Activation of Complement to Treat Alzheimer's$301,495
R01 · FY2006 · AG · contact PI
TGFbeta signaling in neurodegeneration and Alzhimer's$257,808
R01 · FY2006 · AG · contact PI
Drug Agonists of TGFbeta Signaling to Treat Alzheimer's$159,360
R21 · FY2006 · AG · contact PI
Live Imaging of Neuronal Injury in Reporter Mice$104,095
R21 · FY2006 · AG · contact PI
Controlled Activation of Complement to Treat Alzheimer's$308,750
R01 · FY2005 · AG
MECHANISMS OF APOLIPOPROTEIN E-INDUCED NEUROPROTECTION$260,000
R01 · FY2005 · NS
Live Imaging of Neuronal Injury in Reporter Mice$145,632
R21 · FY2005 · AG
Controlled Activation of Complement to Treat Alzheimer's$308,750
R01 · FY2004 · AG
MECHANISMS OF APOLIPOPROTEIN E-INDUCED NEUROPROTECTION$260,000
R01 · FY2004 · NS
Controlled Activation of Complement to Treat Alzheimer's$308,750
R01 · FY2003 · AG
MECHANISMS OF APOLIPOPROTEIN E-INDUCED NEUROPROTECTION$260,000
R01 · FY2003 · NS
Controlled Activation of Complement to Treat Alzheimer's$86,500
R01 · FY2003 · AG
MECHANISMS OF APOLIPOPROTEIN E-INDUCED NEUROPROTECTION$357,000
R01 · FY2002 · NS
Controlled Activation of Complement to Treat Alzheimer's$306,470
R01 · FY2002 · AG
ROLE OF TGF B1 IN CEREBROVASCULAR AMYLOIDOSIS$223,176
R01 · FY2002 · AG
ROLE OF TGF B1 IN CEREBROVASCULAR AMYLOIDOSIS$46,922
R01 · FY2002 · AG
MECHANISMS OF APOLIPOPROTEIN E-INDUCED NEUROPROTECTION$357,000
R01 · FY2001 · NS
ROLE OF TGF B1 IN CEREBROVASCULAR AMYLOIDOSIS$262,234
R01 · FY2001 · AG
ROLE OF TGF B1 IN CEREBROVASCULAR AMYLOIDOSIS$254,594
R01 · FY2000 · AG